<DOC>
	<DOCNO>NCT00348348</DOCNO>
	<brief_summary>This study investigate novel drug candidate treatment bacterial conjunctivitis .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy BOL-303224 Treatment Bacterial Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Clinical diagnosis acute bacterial conjunctivitis exhibit purulent conjunctival discharge redness least one eye . Pregnant nursing female . Use antibiotic within 72 hour enrollment . Any disease condition could interfere safety efficacy evaluation study drug . Participation ophthalmic drug device research study within 30 day prior entry study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>